Efficacy assessment of highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotropin during pituitary suppression in patients undergoing GIFT for unexplained infertility

Gynecological Endocrinology

Volumn 12, Issue 3, 1998, Pages 161-166

  Campo, S ^a   Garcea, N ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Follicle stimulating hormone; GIFT; GnRH analog; Human menopausal gonadotropin; Ovarian stimulation

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM; ENZYME PURIFICATION; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; GAMETE INTRAFALLOPIAN TRANSFER; HUMAN; HYPOPHYSIS FUNCTION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OOCYTE; OOCYTE MATURATION; OVARY FOLLICLE DEVELOPMENT; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; STEROIDOGENESIS; TWINS;

EID: 0031836599     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599809015539     Document Type: Article

References (32)

1. Berger MJ, Taymor ML. The role of luteinizing hormone in human follicular maturation and function. Am J Obstet Gynecol 1971;111:708-10
2. Edelstein MC, Brzyski RG, Jones GS, et al. Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression. Fertil Steril 1990;53:103-6
3. Bomsel-Helmreich O, Vu N, Huyen L, et al. Effects of varying doses of HGC on the evolution of preovulatory rabbit follicles and oocytes. Hum Reprod 1989;4:636-42
4. Jacobs HS, Porter R, Eshel A, et al. Prefertility uses of LHRH agonists analogues. In Vickery BH and Nestor IJ, eds. LH RH and its Analogues: Contraception and Therapeutic Application. Lancaster: MTP Press 1987:303-19
5. Chappel SC, Howles C. Reevaluation of the role of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206-12
6. Insler V, Potashnik G, Lunenfeld E, et al. The combined suppression/stimulation therapy in IVF-ET programmes: expectations and facts. Hum Reprod 1989;4:47-51
7. Neveu S, Hedon B, Bringer J, et al. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilisation. Fertil Steril 1987;47:639-43
8. Bettendorf G, Braendle W, Lichtenberg V, et al. Pharmacologic hypogonadotropism - an advantage for gonadotrophin stimulation. Gynecol Endocrinol 1988;2:66
9. Hughes EG, Fedorkow DM, Daya S, et al. The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intra-Fallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;8: 888-96
10. Tan SL, Maconochie N, Doyle P, et al. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotrophin-releasing hormone agonist buserelin. Am J Obstet Gynecol 1994;71:513-20
11. Tarlatzis BC, Pados G, Bontis J, et al. Ovarian stimulation with buserelin/hMG/hCG: prospective randomized study of short versus long protocol. Hum Reprod 1993;8:807-12
12. Homburg R, Armar AN, Eshel A, et al. The influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovarian syndrome. Br Med J 1988; 297:1024-6
13. Craft I, Brinsden P. Alternatives to IVF: the outcome of 1071 first GIFT procedures. Hum Reprod 1989;4:29-36
14. Penzias AS, Alper MM, Oskowitz SP, et al. Gamete intrafallopian transfer: assessment of the optimal number of oocytes to transfer. Fertil Steril 1991;5: 311-13
15. Hull MGR, Joels LA, Prosser CJ, et al. Experience using preparations of follicle stimulating hormone alone to stimulate the ovaries for assisted conception after pituitary desensitisation and simplified management of treatment. Horm Res 1995;43: 230-7
16. Fleming R, Coutts JRT. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotrophin suppression. Fertil Steril 1986;45:226-30
17. Devroey P, Smitz J, van den Abbee IE, et al. The use of LHRH analogues in IVF/GIFT/ZIFT programmes. Gynecol Endocrinol 1989;3:63-8
18. Russel JB, Lake Polan M, DeCherney AH. The use of pure follicle-stimulating hormone for ovulation induction in normal ovulatory women in an in vitro fertilization program. Fertil Steril 1986;45:829-33
19. Diedrich K, Diedrich C, van der Yen H, et al. Ovarielle stimulation mit reinem FSH in einem In-vitro-Fertilisations-Programm. Geburshilfe Frauenheilkd 1987;47:612-18
20. Daya S. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization: results of a meta-analysis. Horm Res 1995; 43:224-9
21. Devroey P, Tjandraprawira K, Mannaerts B, et al. A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization. Hum Reprod 1995;10: 332-7
22. Torok A, Hamori M, Tinneberg HR, et al. Comparison of the effects of hMG or pure FSH stimulation during suppression with an LHRH agonist analogue. Hum Reprod 1991;6:922-4
23. Duijkers IJM, Vemer HM, Hollanders JMG, et al. Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation. Hum Reprod 1993;8:1387-91
24. Westergaard LG, Erb K, Laursen S, et al. The effect of human menopausal gonadotrophin and highly purified urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in downregulated normogonadotrophic women. Hum Reprod 1996;11:1209-13
25. Balasch J, Fabregues F, Creus M, et al. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization. Hum Reprod 1996;11:2400-4
26. Messinis IE, Templeton A, Baird DT. Comparison between clomiphene plus pulsatile human menopausal gonadotropin and clomiphene plus pulsatile follicle stimulating hormone in induction of multiple follicular development in women. Hum Reprod 1986;1:223-6
27. Diczfalusy E, Harlin J. Clinical-pharmacological studies on human menopausal gonadotrophin. Hum Reprod 1988;3:21-7
28. Meldrum DR, Tsao Z, Monroe SE, et al. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J Clin Endocrinol Metab 1984;58:755-7
29. Parinaud J, Oustry P, Perineau M, et al. Randomized trial of three luteinizing hormone-releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program. Fertil Steril 1992; 57:1265-8
30. Tanbo T, Dale PO, Kjekshus E, et al. Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovarian syndrome. Fertil Steril 1990;53:798-803
31. Hofmann GE, Bentzien F, Bergh PA. Premature luteinization in controlled ovarian hyperstimulation has no adverse effect on oocyte and embryo quality. Fertil Steril 1993;60:675-9
32. Tarlatzis BC, Grimbizis G, Pournaropoulos F, et al. The prognostic value of basal luteinizing hormone: follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques. Hum Reprod 1995;10:2545-9